Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
AssigneeNovo Nordisk HealthCare A/G
InventorRasmus Rojkjaer
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and factor V or a factor V-related polypeptide, and the use thereof for treating bleeding episodes.
Claims19
A pharmaceutically acceptable composition comprising an effective amount of (I) isolated human factor VII and (II) isolated human factor V.
A kit of parts containing a treatment for bleeding episodes comprising:
- a) a container;
- b) an effective amount of a preparation of isolated human factor VII and a pharmaceutically acceptable carrier in a first-unit dosage form;
- and
- c) an effective amount of a preparation of isolated human factor V and a pharmaceutically acceptable carrier in a second-unit dosage form.
A method for treating bleeding episodes in a subject comprising administering to a subject in need thereof a first amount of a preparation of isolated human factor VII and a second amount of a preparation of isolated human factor V, wherein the first and second amounts together are effective to treat bleedings.
A method for reducing clotting time in a subject comprising administering to a subject a first amount of a preparation of isolated human factor VII and a second amount of a preparation of isolated human factor V polypeptide, wherein the first and second amounts together are effective to reduce clotting time.
A method to enhance haemostasis in a subject comprising administering to a subject a first amount of a preparation of isolated human factor VII and a second amount of a preparation of isolated human factor V, wherein the first and second amounts together are effective to enhance haemostasis.
A method for prolonging clot lysis time in a subject comprising administering to a subject a first amount of a preparation of isolated human factor VII and a second amount of a preparation of isolated human factor V, wherein the first and second amounts together are effective to prolong clot lysis time.
A method for increasing clot strength in a subject comprising administering to a subject a first amount of a preparation of isolated human factor VII and a second amount of a preparation of isolated human factor V polypeptide, wherein the first and second amounts together are effective to increase clot strength.
A kit containing a treatment for bleeding episodes comprising a) a container and b) an effective amount of isolated human factor VII, an effective amount of isolated human factor V, and a pharmaceutically acceptable carrier in a single-unit dosage form.
Dependencies are inferred from the claim text.